UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2006

INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter)

Delaware 0-26224 51-0317849 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.)

311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act

_	-	(17 CFR 230.425)
]]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
]]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01. OTHER EVENTS.

ACQUISITION OF CANADA MICROSURGICAL LTD.

On July 11, 2006, Integra LifeSciences Holdings Corporation (the "Company") announced that it is launching a direct sales force in Canada through the acquisition of its longstanding distributor, Canada Microsurgical Ltd. A copy of the press release issued by the Company announcing the acquisition is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit Number Description of Exhibit

99.1 Press release issued July 11, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: July 14, 2006 By: /s/ Stuart M. Essig

Stuart M. Essig

President and Chief Executive Officer

Exhibit Index

Exhibit Number	Description of Exhibit
99.1	Press release issued July 11, 2006

News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III Executive Vice President Chief Administrative Officer (609) 936-2481 jhenneman@Integra-LS.com Maria Platsis Vice President, Corporate Development (609) 936-2333 mplatsis@Integra-LS.com

Integra LifeSciences Announces Direct Sales Strategy in Canada

Acquires Canada Microsurgical Ltd.

Plainsboro, New Jersey/July 11,2006--Integra LifeSciences Holdings Corporation (NASDAQ:IART) announced today that it is launching a direct sales force in Canada through the acquisition of its longstanding distributor, Canada Microsurgical Ltd. Canada Microsurgical has eight sales representatives covering every province in Canada.

"Canada Microsurgical has an outstanding reputation for customer service," said Stuart M. Essig, Integra's Chief Executive Officer. "We are very happy that its skilled sales and distribution operation will form the backbone of our expanding Canadian business."

In addition to the United States and Canada, Integra sells directly to hospitals in France, Germany, the United Kingdom and the Benelux countries.

In 2005, Canada Microsurgical had revenues of C\$8.1 million, reflecting sales of both Integra products and those of other leading medical technology companies. Canada Microsurgical will continue to distribute the products of other companies after the acquisition.

Integra paid C\$6.4 million for Canada Microsurgical at closing. In addition, Integra will pay up to an additional C\$2.1 million over the next three years, depending on the performance of the business. Integra expects the transaction to be neutral to earnings this year and accretive next year.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,600 employees. Please visit our website at (http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning expectations for this newly acquired business and the expected impact of this acquisition on Integra's future financial results. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to successfully integrate Canada Microsurgical into its operations could affect the impact of this acquisition on Integra's future financial results. In addition,

the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation